TRIUMPH-1 - retatrutide in the treatment of obesity in patients without diabetes
Retatrutide is a single-molecule triple-receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors (1):
- simultaneous activation of GIP, GLP-1 and glucagon receptors provides synergistic metabolic control
- GLP-1 and GIP receptor agonism enhances glucose-dependent insulin secretion, delays gastric emptying and reduces central appetite
- is a once-weekly subcutaneous injection for chronic weight management and associated cardiometabolic comorbidities in adults with obesity
- glucagon receptor agonism increases resting energy expenditure and promotes hepatic lipid metabolism while mitigating GLP-1/GIP-driven nausea
TRIUMPH-1 study (1)
- study design: phase 3, randomised, double-blind, placebo-controlled trial evaluating once-weekly retatrutide (4 mg, 9 mg, or 12 mg) over 80 weeks
- study population: 2339 adults with obesity without type 2 diabetes, including pre-specified subgroups with knee osteoarthritis (n=574) and obstructive sleep apnoea (n=243)
- weight loss (primary endpoint):
- 4-mg dose: −17.6% mean weight change vs −3.9% placebo (difference −19.8 percentage points; P<0.001)
- 9-mg dose: −23.7% mean weight change vs −3.9% placebo (difference −21.0 percentage points; P<0.001)
- 12-mg dose: −25.0% mean weight change vs −3.9% placebo (difference −21.0 percentage points; P<0.001)
- knee osteoarthritis pain (co-primary endpoint in subgroup):
- WOMAC pain score reduction (1–10 scale) using hybrid estimand: −3.2 (4 mg), −3.5 (9 mg) and −3.6 (12 mg) vs −1.9 with placebo (differences −1.6 and −1.8 points for 9 mg, and 12 mg vs placebo; P<0.001 for both)
- WOMAC pain score reduction using ITT estimand: −3.4 (4 mg), −3.9 (9 mg) and −4.1 (12 mg) vs −2.5 with placebo (differences −1.4 and −1.6 points for 9 mg, and 12 mg vs placebo; P<0.001 for both)
- obstructive sleep apnoea (co-primary endpoint in subgroup):
- apnoea–hypopnoea index (AHI) event reduction (events/hour) using hybrid estimand: −22.9 (4 mg), −34.3 (9 mg) and −31.7 (12 mg) vs −9.9 with placebo (differences −24.4 and −21.9 for 9 mg and 12 mg vs placebo; P<0.001 for both)
- AHI event reduction using ITT estimand: −22.8 (4 mg), −34.3 (9 mg) and −32.1 (12 mg) vs −9.6 with placebo (differences −24.7 and −22.5 for 9 mg, and 12 mg vs placebo; P<0.001 for both)
Adverse effects and safety profile
- most common adverse events: gastrointestinal effects (including nausea, diarrhoea, constipation and vomiting), predominantly mild-to-moderate in severity during dose escalation
The study authors concluded:
“In adults with obesity, retatrutide resulted in significant weight reduction, reduced pain in participants with knee osteoarthritis, and reduced apnoea–hypopnoea events in participants with obstructive sleep apnoea.”
Reference:
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026 Nov;395(18):1781-1793. doi: 10.1056/NEJMoa2604169.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.